Abstract
Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonists leads to suppression of the levels of circulating androgens, and antiandrogens block the function of the androgen receptor (AR). The steroidal antiandrogen cyproterone acetate and nonsteroidal compounds hydroxyflutamide and bicalutamide are used most frequently. They prevent acquisition of a transcriptionally active conformation of the AR. It became clear that tumors progress to therapy resistance in the presence of the AR which might be structurally altered. These mutations generate receptors that respond to other steroids and antiandrogens by increased activation. In addition, AR expression increases during endocrine treatment. AR is also activated by nonsteroidal compounds such as growth factors, interleukin-6, and neuropeptides. Therefore, new experimental approaches are needed to antagonize AR expression and function more efficiently. The AR associates with a number of proteins, coactivators and corepressors. There are indications that expression of some of these proteins is altered in prostate cancer, a fact which might be important for improvement of endocrine therapy.
Keywords: Antiandrogens, luteinizing hormone releasing hormone (LHRH), nonsteroidal, corepressors, proteins
Current Cancer Drug Targets
Title: Antiandrogens in Prostate Cancer Endocrine Therapy
Volume: 4 Issue: 5
Author(s): Z. Culig, G. Bartsch and A. Bartsch
Affiliation:
Keywords: Antiandrogens, luteinizing hormone releasing hormone (LHRH), nonsteroidal, corepressors, proteins
Abstract: Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonists leads to suppression of the levels of circulating androgens, and antiandrogens block the function of the androgen receptor (AR). The steroidal antiandrogen cyproterone acetate and nonsteroidal compounds hydroxyflutamide and bicalutamide are used most frequently. They prevent acquisition of a transcriptionally active conformation of the AR. It became clear that tumors progress to therapy resistance in the presence of the AR which might be structurally altered. These mutations generate receptors that respond to other steroids and antiandrogens by increased activation. In addition, AR expression increases during endocrine treatment. AR is also activated by nonsteroidal compounds such as growth factors, interleukin-6, and neuropeptides. Therefore, new experimental approaches are needed to antagonize AR expression and function more efficiently. The AR associates with a number of proteins, coactivators and corepressors. There are indications that expression of some of these proteins is altered in prostate cancer, a fact which might be important for improvement of endocrine therapy.
Export Options
About this article
Cite this article as:
Culig Z., Bartsch G. and Bartsch A., Antiandrogens in Prostate Cancer Endocrine Therapy, Current Cancer Drug Targets 2004; 4 (5) . https://dx.doi.org/10.2174/1568009043332925
DOI https://dx.doi.org/10.2174/1568009043332925 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Integrative System Biology Strategies for Disease Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis
Recent Patents on Anti-Cancer Drug Discovery Smart Stimuli Sensitive Nanogels in Cancer Drug Delivery and Imaging: A Review
Current Pharmaceutical Design An Overview on Pyranocoumarins: Synthesis and Biological Activities
Current Organic Chemistry Diagnostic and Therapeutic Use of Membrane Proteins in Cancer Cells
Current Medicinal Chemistry The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy
Current Topics in Medicinal Chemistry Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews A Study on the Biological Activity of 2-thioxo-imidazolidin-4-ones
Letters in Drug Design & Discovery Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Current Cancer Drug Targets Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Preparation and Characterization of Highly Fluorescent TGA-CdTe Quantum Dot-Hyamine 1622 Additive Composite
Micro and Nanosystems Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Xiaoyao Pill Improves the Affective Dysregulation of Sleep-deprived Female Mice by Inhibiting Brain Injury and Regulating the Content of Monoamine Neurotransmitter
Current Pharmaceutical Biotechnology Synthesis of New Cyanopyridine Scaffolds and their Biological Activities
Current Organic Synthesis Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Short, but Highly Concentrated, Direct Inhalations of Essential Oil Molecules Improve Poor Sleep Quality: A Natural History Controlled, Withingroup, Self-administration Field Pilot Study
Current Psychopharmacology Chemotherapeutic Targeting of Cell Death Pathways
Anti-Cancer Agents in Medicinal Chemistry Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1
Anti-Cancer Agents in Medicinal Chemistry